



Who we are

PHOENIX unites paediatric care, research, industry and patient groups to develop safer, more effective treatments for relapsed or refractory neuroblastoma and solid tumours

What we are working on

A first-in-child Phase I/II trial tests oral ibrilatazar with established treatments, alongside biomarker, pharmacokinetic, patient-reported and social determinants studies.

What's the one thing we need next

We need European networks, researchers and patient organisations to strengthen recruitment, evidence and equitable access, accelerating translation of promising results into better care.



5 years Mission Cancer:
Stronger Through Connection

BRUSSELS

29 SEPTEMBER – 01 OCTOBER



For more info visit:
www.phoenix-project.eu



EUROPEAN UNION

PHOENIX

Phase I/II trial of an Oral ER-stress iNducer
in relapsed/refractory neuroblastoma
and paediatric solid tumours.

